A Dose Block-randomized, Double-blind, Placebo Controlled, Dose-escalation Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Oral Dose of HL237 in Healthy Male Subject
Latest Information Update: 02 Mar 2021
At a glance
- Drugs HL-237 (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Hanlim Pharmaceutical
Most Recent Events
- 08 Apr 2019 New trial record